It’s only fair to share… Cetagliptin CAS No. FREE FORM : 2243737-33-7 C18H18F6N4O, 420.4 g/mol [ Cetagliptin Phosphate 2243737-33-7 ] 분자량 MW 518.35 화학식 MF C18H21F6N4O5P (3R)-3-amino-1-[(8R)-8-methyl-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one (3R)-3-amino-1-[(8R)-8-methyl-3-(trifluoromethyl)-6,8-dihydro-5H-imidazo[1,5-a]pyrazin-7-yl]-4-(2,4,5-trifluorophenyl)butan-1-one CHINA 2024, APPROVALS 2024, CGeneTec, DIABETES, RegisteredType 2 diabetes mellitus CHINA 2024 Cetagliptin (CGT-8012) is an orally bioavailable, dipeptidyl peptidase 4 enzyme (DPP-4) inhibitor (‘gliptin’) class drug. It was …
Cofrogliptin
It’s only fair to share… Cofrogliptin HSK 7653 (2R,3S,5R,6S)-2-(2,5-difluorophenyl)-5-(2-methylsulfonyl-4,6-dihydropyrrolo[3,4-c]pyrazol-5-yl)-6-(trifluoromethyl)oxan-3-amine APPROVALS 2024, CHINA 2024, Haisco Pharmaceutical Group Co, Beichangping, DIABETES Cofrogliptin (developmental name HSK7653) is a long-acting DPP4 inhibitor dosed once every two weeks.[1][2][3][4] Cofrogliptin (HSK7653) (compound 2), a tetrahydropyran derivative, is a potent oral dipeptidyl aminopeptidase 4 (DPP-4) inhibitor with Long-acting antidiabetic efficacy. Cofrogliptin (compound 2) has a great potential for type 2 …
Janagliflozin
It’s only fair to share… Janagliflozin WeightAverage: 460.95Monoisotopic: 460.1652664 Chemical FormulaC25H29ClO6 China 2024, approvals 2024, Jilin Huisheng Biopharmaceutical Co, sihuan, SGLT2 inhibitors, Huiyoujing Janagliflozin is an SGLT2 inhibitor developed by Sihuan Pharmaceutical.[1][2][3][4][5][6] It is approved in China for the treatment of type 2 diabetes.[7] PAPER https://www.thieme-connect.de/products/ejournals/abstract/10.1055/s-0042-1751524 (71) (a) Wu, F. US9315438B2, 2016. (b) Wu, F. EP2891654A1, 2014. Initially, the two advanced …
Zorifertinib
It’s only fair to share… Zorifertinib AZD 3759 CAS 1626387-80-1, 67SX9H68W2 WeightAverage: 459.91Monoisotopic: 459.1473455 Chemical FormulaC22H23ClFN5O3 [4-(3-chloro-2-fluoroanilino)-7-methoxyquinazolin-6-yl] (2R)-2,4-dimethylpiperazine-1-carboxylate China 2024, APPROVALS 2024, Alpha Biopharma, ASTRA ZENECA, Zorifer, Zorifertinib (AZD3759) is a drug for the treatment of cancer.[1] In China, it was approved in 2024 for locally advanced or metastatic non-small-cell lung cancer (NSCLC) that has epidermal growth factor receptor exon 19 …
Garsorasib
It’s only fair to share… Garsorasib Chemical Formula: C32H32F2N8O2 Exact Mass: 598.2616 Molecular Weight: 598.66 D 1553, Chia Tai Tianqing, CHINA 2024, APPROVALS 2024, Anfangning, Garsorasib is an orally available inhibitor of the oncogenic KRAS substitution mutation, G12C, with potential antineoplastic activity. Upon oral administration, garsorasib selectively targets the KRAS G12C mutant and inhibits KRAS G12C mutant-dependent signaling. …
Fulzerasib
It’s only fair to share… Fulzerasib GFH925 CAS No. : 2641747-54-6 Molecular Weight 617.07 Formula C32H30ClFN6O4 (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione (7R)-16-chloro-15-(2-fluoro-6-hydroxyphenyl)-9-methyl-12-(4-methyl-2-propan-2-ylpyridin-3-yl)-5-prop-2-enoyl-2,5,9,12,14-pentazatetracyclo[8.8.0.02,7.013,18]octadeca-1(10),13,15,17-tetraene-8,11-dione CHINA 2024, APPROVALS 2024, Innovent Biologics, DUPERT Fulzerasib (Dupert®; Innovent Biologics/GenFleet Therapeutics) is an orally active small molecule inhibitor of the KRAS G12C mutant protein being developed for the treatment of solid tumors harboring the KRAS G12C oncogenic …
Golidocitinib
It’s only fair to share… Golidocitinib CAS 2091134-68-6 WeightAverage: 489.584Monoisotopic: 489.260071274 Chemical FormulaC25H31N9O2 (2R)-N-[3-[2-[(3-methoxy-1-methylpyrazol-4-yl)amino]pyrimidin-4-yl]-1H-indol-7-yl]-2-(4-methylpiperazin-1-yl)propanamide Approvals 2024, china 2024, DZD 4205, DIZAL, Gao Ruizhe, Golidocitinib is a pharmaceutical drug for the treatment of cancer. In June 2024, it was given conditional approval in China for the treatment of relapsed or refractory peripheral T-cell lymphoma.[1] Golidocitinib is classified as …
Oritinib
It’s only fair to share… Oritinib CHINA 2024, Nanjing Sanhome Pharmaceutical. N-[2-[2-(dimethylamino)ethyl-methylamino]-4-methoxy-5-[[4-(6,7,8,9-tetrahydropyrido[1,2-a]indol-10-yl)pyrimidin-2-yl]amino]phenyl]prop-2-enamide Oritinib is an investigational new drug currently under investigation for its potential use in cancer treatment.[1][2] As a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, oritinib targets specific enzymes involved in the signaling pathways that regulate cell division and survival, which are often dysregulated in cancer cells.[1] Oritinib (SH-1028), …
Envonalkib
It’s only fair to share… Envonalkib TQ-B3139, Chia Tai Tianqing, Anluoqing, cancer ENVONALKIB is a small molecule drug with a maximum clinical trial phase of II and has 1 investigational indication. SYN WO2014117718 https://patentscope.wipo.int/search/en/WO2014117718 Example 27: 5-[(2,6-dichloro-3-fluorophenyl)ethoxy-4′-methoxy-6′ … Step 1: 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4′-methoxy-6′-((S)-2-methyl-4-tert-butoxycarbonylpiperazin-1-yl)-3,3′-bipyridin-6-amine To dioxane (10 mL) and water (1.5 mL) were added tert-butyl (S)-4-(5-bromo-4-methoxypyridin-2-yl)-3-methylpiperidin-1-carboxylate (106 mg, …
Brensocatib
It’s only fair to share… Brensocatib WeightAverage: 420.469Monoisotopic: 420.179755269 Chemical FormulaC23H24N4O4 (2S)-N-[(1S)-1-cyano-2-[4-(3-methyl-2-oxo-1,3-benzoxazol-5-yl)phenyl]ethyl]-1,4-oxazepane-2-carboxamide FDA 8/12/2025. Brinsupri, To treat non-cystic fibrosis bronchiectasis Brensocatib is an investigational new drug that is being evaluated to treat bronchiectasis.[1] It is a dipeptidyl-peptidase I (also known as cathepsin C) inhibitor.[2] A phase 3 clinical trial, known as the ASPEN trial, was conducted to evaluate the safety and efficacy of …